Related Experiment Video

Updated: May 16, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose

Andrew C Philpott1, Jaroslav Hubacek, Yichun C Sun

  • 1Department of Cardiology, Lyell McEwin Hospital, Elizabeth Vale, Adelaide, South Australia 5000, Australia. aphilp02@gmail.com

Atherosclerosis
|November 24, 2012
PubMed

Insights

Extended-release niacin improved lipid profiles in coronary artery disease patients on statins but did not enhance endothelial or microvascular function. This study evaluated niacin

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Vascular Biology

Background:

  • Endothelial dysfunction is prevalent in coronary artery disease (CAD) and impacts prognosis.
  • Niacin demonstrates clinical benefits in CAD patients, but its added value alongside statin therapy requires investigation.
  • The effect of niacin on endothelial function with optimal LDL cholesterol levels remains unclear.

Purpose of the Study:

  • To assess the impact of extended-release (ER) niacin on endothelial and vascular function in CAD patients receiving high-dose statins.
  • To evaluate changes in brachial flow-mediated dilatation (FMD), peak hyperemic velocity (VTiRH), and pulse arterial tonometry (PAT).

Main Methods:

  • A randomized crossover study involving 66 CAD patients treated with atorvastatin 80 mg daily.
  • Patients received ER niacin (1500 mg/day) or placebo for 3 months each.
  • Endothelial and vascular function were measured using FMD, VTiRH, and PAT at baseline and after each treatment period.

Main Results:

  • Niacin significantly improved lipid profiles, lowering LDL and raising HDL cholesterol compared to placebo.
  • No significant improvements were observed in FMD, VTiRH, or PAT measurements with niacin treatment.
  • Lipid profile improvements did not correlate with enhanced endothelial or microvascular function.

Conclusions:

  • ER niacin as an adjunct to high-dose statins in CAD patients effectively improves lipid profiles.
  • Despite lipid improvements, niacin did not enhance endothelial or microvascular function in this patient cohort.
  • Further research is needed to understand niacin's role in vascular health for CAD patients on statins.
Abstract

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Angina V: Nursing Management01:20

Angina V: Nursing Management

Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...